Skip to main content
Clinical Trials/NCT05267626
NCT05267626
Recruiting
Phase 1

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Aulos Bioscience, Inc.31 sites in 2 countries159 target enrollmentApril 4, 2022

Overview

Phase
Phase 1
Intervention
Aldesleukin
Conditions
Not specified
Sponsor
Aulos Bioscience, Inc.
Enrollment
159
Locations
31
Primary Endpoint
Evaluate the safety and tolerability of AU-007
Status
Recruiting
Last Updated
2 months ago

Overview

Brief Summary

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.

Detailed Description

This is a first in human, multicenter, open-label Phase 1-2 study evaluating the safety, tolerability, and initial efficacy of AU-007 with or without aldesleukin, in patients with unresectable locally advanced or metastatic cancer. Patients must either be ineligible for or have progressed on prior standard of care therapy. Part 1 consists of 3 escalation Arms, each starting with a single 1+2 escalation cohort followed by 3+3 escalation cohorts to define the RP2D or maximum tolerated dose (MTD). The study begins in Arm A evaluating escalating doses of AU-007 (Q2w) in sequential escalation cohorts to define RP2D or MTD. In Arm B, AU-007 (Q2w) is evaluated in combination with a single dose of aldesleukin given with the first AU-007 dose. AU-007 is administered Q2w with an escalating single aldesleukin dose in sequential escalation cohorts. In Arm C, AU-007 is evaluated in combination with aldesleukin, both given Q2w. AU-007 will be administered with an escalating dose of aldesleukin in each sequential Arm C escalation cohort. The Part 2 cohort expansion portion of the study consists of up to three expansion Arms evaluating the initial efficacy of the RP2D (AU-007 plus a single loading dose of aldesleukin) in selected solid tumor types, prioritizing cutaneous melanoma and non-small cell lung cancer (NSCLC). Part 3 evaluates the safety of AU-007 in combination with aldesleukin and avelumab, followed by one expansion cohort, in NSCLC. Part 4 evaluates the safety of AU-007 plus aldesleukin in combination with nivolumab, followed by one expansion cohort, in cutaneous melanoma.

Registry
clinicaltrials.gov
Start Date
April 4, 2022
End Date
June 12, 2026
Last Updated
2 months ago
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Selected Inclusion Criteria:
  • Patients must have measurable disease as per RECIST v1.1 criteria and documented by CT and/or MRI
  • Part 2 includes but is not limited to:
  • Cutaneous melanoma that is either locally unresectable or metastatic:
  • BRAF wild type: progressed after receiving PD-1 containing therapy with or without an anti-CTLA-4
  • BRAF mutation: patients who refused BRAF+MEK inhibitor
  • Must have objective progression after receiving at least two cycles of prior doublet therapy (anti-PD-1/anti-CTLA-4 or anti-PD-1/anti-LAG-3)
  • Radiographic progression ≥ 4 weeks prior to the first dose of study drug to rule out late response to most recent therapy. The requirement for documented radiologic progression may be waived after review by Medical Monitor (e.g., in the case of progression beyond 12 weeks after starting a doublet)
  • LDH ≤ 2.5 x ULN
  • NSCLC: Unresectable locally advanced or metastatic PD-L1-positive (tumor proportion score \[TPS\] ≥ 1%) NSCLC not harboring an activating EGFR mutation or ALK rearrangement and has progressed during or following treatment with an anti-PDx with or without platinum-based chemotherapy

Exclusion Criteria

  • Patients with a history of known autoimmune disease with exceptions of
  • Psoriasis, atopic dermatitis, or other autoimmune skin condition not requiring systemic treatment
  • History of Graves' disease in patients now euthyroid for \> 4 weeks
  • Hypothyroidism managed by thyroid hormone replacement
  • Arthritis managed without systemic therapy beyond oral nonsteroidal anti- inflammatory drugs
  • Major surgery or traumatic injury within 3 weeks before first dose of AU-007
  • Unhealed wounds from surgery or injury
  • Treatment with \> 10 mg per day of prednisone (or equivalent) or other immune-suppressive drugs within the 7 days prior to the initiation of study drug. Steroids for topical, ophthalmic, inhaled, or nasal administration are allowed
  • Prior anti-cancer therapy before the planned start of AU-007 as follows:
  • Not recovered to baseline from toxicity of prior systemic cancer therapy(ies).

Arms & Interventions

AU-007 plus aldesleukin in combination with nivolumab

AU-007 (Q2w) administered in combination with a single dose of aldesleukin with the initial AU-007 dose. Nivolumab will be administered Q4w.

Intervention: Aldesleukin

AU-007 Monotherapy

AU-007 (Q2w) administered as a monotherapy sequential ascending doses with each Dose Escalation Cohort (Complete; no longer enrolling)

Intervention: AU-007

AU-007 combined with a single dose of aldesleukin

AU-007 (Q2w) administered in combination with a single dose of aldesleukin with the initial AU-007 dose.

Intervention: AU-007

AU-007 combined with a single dose of aldesleukin

AU-007 (Q2w) administered in combination with a single dose of aldesleukin with the initial AU-007 dose.

Intervention: Aldesleukin

AU-007 combined with aldesleukin given concomitantly

AU-007 administered in combination with aldesleukin, both administered Q2w (Complete; no longer enrolling)

Intervention: AU-007

AU-007 combined with aldesleukin given concomitantly

AU-007 administered in combination with aldesleukin, both administered Q2w (Complete; no longer enrolling)

Intervention: Aldesleukin

AU-007 plus aldesleukin in combination avelumab

AU-007 and avelumab administered Q2w with a single dose of aldesleukin with the initial AU-007 dose

Intervention: AU-007

AU-007 plus aldesleukin in combination avelumab

AU-007 and avelumab administered Q2w with a single dose of aldesleukin with the initial AU-007 dose

Intervention: Aldesleukin

AU-007 plus aldesleukin in combination avelumab

AU-007 and avelumab administered Q2w with a single dose of aldesleukin with the initial AU-007 dose

Intervention: Avelumab

AU-007 plus aldesleukin in combination with nivolumab

AU-007 (Q2w) administered in combination with a single dose of aldesleukin with the initial AU-007 dose. Nivolumab will be administered Q4w.

Intervention: AU-007

AU-007 plus aldesleukin in combination with nivolumab

AU-007 (Q2w) administered in combination with a single dose of aldesleukin with the initial AU-007 dose. Nivolumab will be administered Q4w.

Intervention: Nivolumab

Outcomes

Primary Outcomes

Evaluate the safety and tolerability of AU-007

Time Frame: Day 1 thru end of treatment (EOT) visit (28 days after last dose)

Measured by the frequency of DLTs (Dose limiting toxicity) and safety profile

Establish the maximum tolerated dose (MTD) and/or RP2D

Time Frame: Day 1 thru EOT visit (28 days after last dose)

With AU-007 alone or in combination with aldesleukin measured by pharmacokinetics (PK), pharmacodynamics (PD), and Biomarkers

Secondary Outcomes

  • Magnitude of immunogenicity after dosing with AU-007 alone or in combination with aldesleukin, AU-007 in combination with aldesleukin and avelumab or nivolumab(Day 1 thru EOT visit (28 days after last dose))
  • Magnitude of PK changes in the blood after dosing determined by area under the curve (AUC) of AU-007(Day 1 thru EOT visit (28 days after last dose))
  • Magnitude of PK changes in the blood after dosing determined by maximum concentration (Cmax) of AU-007(Day 1 thru EOT visit (28 days after last dose))
  • Magnitude of PK changes in the blood after dosing determined by time of maximum concentration (Tmax)(Day 1 thru EOT visit (28 days after last dose))
  • Magnitude of PK changes in the blood after dosing determined by Half-life (T1/2) of AU-007(Day 1 thru EOT visit (28 days after last dose))
  • Magnitude of cytokine changes in the blood after dosing(Day 1 thru EOT visit (28 days after last dose))
  • Evaluate the preliminary anti-tumor activity of AU-007 alone, in combination with aldesleukin, in combination with aldesleukin and avelumab, and AU-007 plus aldesleukin with nivolumab in patients with unresectable locally advanced or metastatic cancer(Day 1 thru EOT visit (28 days after last dose))

Study Sites (31)

Loading locations...

Similar Trials

Related News

Aulos Bioscience to Present Updated Phase 2 Data for AI-Designed Imneskibart in Checkpoint Inhibitor-Refractory Cancers at SITC 2025- Aulos Bioscience will present updated Phase 2 data for imneskibart (AU-007) in checkpoint inhibitor-refractory melanoma and non-small cell lung cancer at the SITC 40th Annual Meeting in November 2025. - Imneskibart is a human monoclonal antibody designed using artificial intelligence that selectively binds IL-2 and prevents CD25 binding to redirect immune responses toward tumor killing. - The novel mechanism prevents IL-2 from binding to regulatory T cells while allowing effector T cell and NK cell expansion, potentially reducing toxicities associated with traditional IL-2 therapy. - The presentation will occur on November 7, 2025, as part of the Society for Immunotherapy of Cancer meeting held in National Harbor, Maryland.Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic in Melanoma Treatment- Aulos Bioscience will present new Phase 2 data for AU-007, an AI-designed monoclonal antibody targeting IL-2, showing promising results in second-line melanoma treatment at the upcoming AACR Annual Meeting. - AU-007's unique mechanism prevents IL-2 from binding to regulatory T cells while allowing it to activate effector T cells and NK cells, potentially overcoming limitations of traditional IL-2 therapies. - The novel therapeutic may significantly reduce serious side effects associated with high-dose IL-2 therapy, including vascular leak syndrome and pulmonary edema, by preventing IL-2 binding to CD25-containing receptors.Aulos Bioscience Doses First Patient in Phase 2 NSCLC Trial of AU-007, Avelumab, and Aldesleukin Combination- Aulos Bioscience has dosed the first patient in a Phase 2 trial evaluating AU-007, avelumab, and low-dose aldesleukin for non-small cell lung cancer (NSCLC). - The trial is a collaboration with Merck KGaA and focuses on second-line treatment for PD-L1+ NSCLC patients who have progressed after first-line checkpoint inhibitor therapy. - Preclinical data showed the combination of AU-007 with avelumab and IL-2 resulted in strong anti-cancer activity, including complete tumor eradication. - Aulos Bioscience plans to share preliminary data from this Phase 2 cohort in the first half of 2025.Aulos Bioscience's AU-007 Shows Promise in Phase 1/2 Trial with Novel IL-2 Therapeutic Approach- Aulos Bioscience presented data on AU-007, a novel IL-2 therapeutic, at the EORTC-NCI-AACR Symposium, highlighting its unique mechanism of action. - AU-007 demonstrated Treg reduction correlated with longer progression-free survival and increased effector T cells, suggesting potential clinical benefits. - Phase 2 expansion cohorts are ongoing in renal cell carcinoma, melanoma, and non-small cell lung cancer to evaluate optimal dosing schedules. - The AI-designed antibody shows a manageable safety profile, with no vascular leak syndrome or pulmonary edema observed in the evaluated dose levels.Aulos Bioscience's AU-007 Shows Promise in Phase 2 Solid Tumor Trial- Aulos Bioscience is set to present Phase 2 data on AU-007, a novel IL-2 therapeutic antibody, at the SITC 2024 Annual Meeting. - AU-007 uniquely targets the CD25-binding portion of IL-2, enhancing anti-tumor immunity by selectively activating effector T cells and NK cells. - The Phase 2 trial data includes early results in melanoma and renal cell carcinoma, building on previously presented positive clinical data. - AU-007 aims to improve upon traditional IL-2 therapies by reducing immunosuppression and toxicities like vascular leak syndrome.